文献速递中医内科中药与中成药合理使用

乳癖散结胶囊治疗乳腺疼痛的系统评价与Meta分析

Chinese herbal medicine (Rupi Sanjie capsule) for the treatment of breast pain: A systematic review and meta-analysis of randomized clinical trials.
PubMed 文献 · Integr Med Res · 2020-07-31

该系统评价纳入17项RCT共2899例乳腺疼痛患者,比较乳癖散结胶囊与他莫昔芬等药物。Meta分析显示乳癖散结胶囊在缩短疼痛和肿块持续时间、提高临床治愈率和总有效率方面优于他莫昔芬,且总不良事件发生率更低,但证据质量普遍较弱。

要点

  • 乳癖散结胶囊可缩短乳腺疼痛持续时间(MD -6.51天)和肿块持续时间(MD -5.17天)。
  • 与他莫昔芬相比,乳癖散结胶囊提高临床治愈率(RR 1.55)和总有效率(RR 1.08)。
  • 乳癖散结胶囊总不良事件发生率低于他莫昔芬(RR 0.30),但证据强度有限。

核心结论

  • 乳癖散结胶囊治疗乳腺疼痛可能有效且总体安全,但证据质量普遍较弱,结论尚不确定。

研究设计与样本

  • 系统评价与Meta分析,检索6个数据库至2020年6月1日,纳入17项随机对照试验,共2899例乳腺疼痛患者。

主要发现

  • 与他莫昔芬相比,乳癖散结胶囊缩短乳腺疼痛持续时间(MD -6.51天,95%CI [-8.57, -4.45],n=82,1项试验)。
  • 与他莫昔芬相比,乳癖散结胶囊缩短乳腺肿块持续时间(MD -5.17天,95%CI [-7.56, -2.78],n=82,1项试验)。
  • 与他莫昔芬相比,乳癖散结胶囊提高临床治愈率(RR 1.55,95%CI [1.21, 2.00],I²=64%,n=1398,10项试验)。
  • 与他莫昔芬相比,乳癖散结胶囊提高总有效率(RR 1.08,95%CI [1.03, 1.14],I²=71%,n=2170,14项试验)。
  • 他莫昔芬组总不良事件发生率高于乳癖散结胶囊组(RR 0.30,95%CI [0.21, 0.42],I²=49%,n=2122,13项试验)。

临床怎么用

  • 乳癖散结胶囊可作为乳腺疼痛的潜在治疗选择,尤其适用于需避免他莫昔芬不良反应的患者。
  • 临床应用时应结合患者具体情况,并充分告知证据质量较弱的局限性。

局限性

  • 纳入试验的方法学质量普遍较弱,证据强度有限,潜在获益尚不确定。
  • 部分结局指标仅基于单项试验(如疼痛和肿块持续时间),样本量小。
  • 结论需进一步在大样本、严谨设计的试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast pain is one of the most common breast disorders, affecting 41%-69% women in the clinical populations. Chinese herbal medicine (Rupi Sanjie, RPSJ) capsule has been recommended to be commonly used for breast pain in China. This review aimed to systematically collect latest evidence and critically evaluate the eff ;ectiveness and safety of RPSJ capsule for breast pain. METHODS: We searched 6 databases from their inception to June 1, 2020 for randomized clinical trials (RCTs) comparing RPSJ capsule with conventional drug therapies, placebo or no treatment. Primary outcomes were breast pain relief, reduction of breast mass and clinical cure rate. RESULTS: Seventeen RCTs were included in total, involving 2899 participants with breast pain. RPSJ capsule showed a significant effects in shortening duration of the breast pain (MD-6.51 days, 95%CI [-8.57, -4.45], n = 82, 1 trial), shortening the duration of breast mass (MD-5.17 days, 95%CI [-7.56, -2.78], n = 82, 1 trial), improving clinical cure rate (RR 1.55, 95% CI [1.21, 2.00], I² = 64%, n = 1398, 10 trials) and total effective rate (RR 1.08, 95% CI [1.03, 1.14], I² = 71%, n = 2170, 14 trials) compared to Tamoxifen (TAM). The meta-analysis showed that the incidence of total adverse events was higher in TAM group than the RPSJ capsule group (RR 0.30, 95%CI [0.21, 0.42], I² = 49%, n = 2122, 13 trials). CONCLUSIONS: RPSJ capsule appears to be a potentially effective in treating breast pain and seems generally safe for clinical application. However, this potential benefit is inconclusive due to generally weak evidence, and the findings should be further confirmed in large and rigorous trials.

来源:Integr Med Res,查看原文。版权归原作者所有。

引用

  1. Lai BY, Jia LY, Yu BW, et al. Chinese herbal medicine (Rupi Sanjie capsule) for the treatment of breast pain: A systematic review and meta-analysis of randomized clinical trials. Integr Med Res. 2020. PMID: 33134080. doi:10.1016/j.imr.2020.100491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。